Teal Health Raises $22 Million Series A to Expand Access to the Most Accurate FDA-Authorized At-Home HPV Cervical Cancer Screening
Teal Health, creators of the Teal WandTM, the first and most accurate FDA-authorized self-collection device for at-home HPV cervical cancer screening, led by Kara Egan, has announced $22 million in Series A funding led by .406 Ventures, with continued backing from Emerson Collective (managed by Yosemite), Forerunner, and Serena Ventures, and new participation from Japan-based MPower Partners. The financing brings Teal Health’s total funding to $45 million.
The funding comes at a critical moment, with nearly one in three U.S. women not up to date on cervical cancer screening, partly due to physician shortages and limited appointment availability that make traditional in-office screening harder to access.
Expanding preventive care options for women is becoming increasingly important. Teal is addressing this gap with an at-home screening alternative, ahead of January 2027 federal guidelines requiring most health plans to cover self-collection for cervical cancer screening.
The new funding will expand Teal Health’s network of partnerships across payors, health systems, employers, providers, and brands, making at-home screening available across more healthcare and consumer touchpoints. The company is also expanding direct-purchase options for individuals and organizations, with the goal of making at-home screening a routine part of preventive care nationwide.
The funding will also support hiring across clinical, commercial, technology, and operational teams as Teal scales its reach.
“We designed Teal for all women, whether they are behind on their screening or coming due. Screening is just too difficult today, whether that is finding an appointment, the time in your day to attend, or the physical discomfort. Women need an accurate, trusted alternative that makes it easy to screen,” said Kara Egan, CEO and Co-Founder of Teal Health.
“This funding allows us to scale to meet the demand of patients and providers. It’s clear this option is preferred by women, and now we can ensure everyone has a way to stay healthy.”
The Teal Wand is an FDA-authorized self-collection device for at-home HPV cervical cancer screening, eliminating the need for a speculum or in-office visit. Teal Health combines private, at-home sample collection with telehealth, secure results delivery, and follow-up care when needed.
The platform is reaching an underserved population, with 59% of Teal users considered underscreened. Thousands of women have rated the end-to-end experience an average of 4.95 out of 5, highlighting strong demand for a more accessible screening experience.
"Patients are demanding more convenient ways to access healthcare, and Teal has proven that convenience doesn’t have to come at the expense of accuracy," said Kathryn Taylor Reddy, Partner at .406 Ventures.
"With insurance coverage expanding in 2027, Teal Health is positioned to transform how millions of women receive essential preventive healthcare.”
Since receiving FDA authorization in 2025, Teal Health has screened thousands of women nationwide, contributed to national screening guidelines, and advanced self-collection research through 17 peer-reviewed papers and presentations. Partnerships with health systems, providers, employers, and payers are expanding access to the Teal Wand while helping close screening gaps and reduce pressure on clinics.
The latest funding will deepen these partnerships and expand direct access for organizations and individuals, helping move at-home cervical cancer screening from early adoption into routine preventive care.
𝐑𝐞𝐦𝐨𝐭𝐞 𝐇𝐢𝐫𝐞 𝐨𝐫 𝐁𝐮𝐢𝐥𝐝 𝐖𝐢𝐭𝐡 𝐔𝐬: 𝐁𝐮𝐢𝐥𝐝𝐰𝐞𝐫𝐤𝐬 helps technology companies build in India: two ways. Hire vetted remote engineers, product leaders, designers, and GTM professionals directly onto your team. Or partner with a proven development studio to design, build, and ship your product end-to-end. Learn More At: menlotimes.com/buildwerks
